ADC Development for Renal Cancer

Renal cancer is a common tumor, the third malignancy within urological oncology and comprises 2-3% of all malignancies. Traditional treatment for the cancer like chemo- and radiotherapy show poor response. As an emerging novel and promising anticancer treatment agent, Antibody-drug conjugate (ADC) combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. As an experienced CRO company specialized in ADC Development, Creative Biolabs offers custom ADCs development services against renal cancer. Our services will effectively save the time and cost of your discovery programs by taking advantage of our expertise and innovative technology platforms.

Introduction of Renal Cancer

Renal cancer or kidney cancer is a type of cancer that begins in the kidney, which mainly originates in two parts of the kidney, the renal tubule and the renal pelvis. Usually, there is no obvious symptom in the early stages of renal cancer. In the later stages, symptoms generally include blood in the urine, a lump or mass in the kidneys and abdomen, continuous pain, anemia, constant fever and night sweats, tiredness or fatigue, weight loss and loss of appetite. Risk factors of the cancer include age, sex, obesity, smoking, hypertension, exposed to chemicals, urinary tract infections and family history. Renal cancer represents one of the 10 most common cancers, which occurs more frequently among adults aged between 50 and 80 years. Currently, North America accounts for the highest rate of renal cancer, and the incidence presents a steady increase in developing countries over the last decades. The main types of renal cancer include renal cell carcinoma (RCC), transitional cell cancer (TCC), and Wilms tumor, and RCC makes up approximately 80% of kidney cancers.

Renal cancer (kidney cancer). Fig.1 Renal cancer (kidney cancer).

Current Therapeutic Strategies for Renal Cancer

To date, treatments for the renal cancer include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Traditional cytotoxic chemotherapies often have low responses, such as the vinblastine, 5-fluorouracil (5-FU), gemcitabine and Capecitabine, which also can cause the refractory of renal cancer. If patients present metastatic disease, surgery is another essential option in the treatment of the cancer but limited. Besides, non-specific immunotherapy such as the cytokine therapy (IFN-α and IL-2) is extensively studied for the treatment of metastatic disease (mRCC). Immunochemotherapy is also under investigated actively, the most frequently used combination is IFN-α and a cytostatic agent called vinblastine. Also, other cytostatic agents, such as cyclophosphamide, epirubicin, floxuridin, ifosfamide and mitomycin, show no clear additional effect on the response rate in combination with INF-α.

Recently, targeted immunotherapy is showing significant advantages in cancer therapy. These therapeutic agents include the tyrosine kinase inhibitors (sunitinib, pazopanib, and sorafenib), the monoclonal antibody (bevacizumab), and the rapamycin analogs (temsirolimus and everolimus), which are approved agents in the United States for the treatment of metastatic RCC. In addition, ADCs such as the AMG 172, AGS‑16C3F, CDX‑014, HKT288, SGN‑CD70A and Vorsetuzumab mafodotin (also known as SGN‑75) have entered different stages of clinical trials.

Emergence of cancer treatment options. Fig.2 Emergence of cancer treatment options.

What Can We Do for You?

Conventional therapies are considered to be of limited value for the treatment of renal cancer, because they don’t significantly change response rates or survival. Targeted therapies now play a required role in the cancer treatment, especially the ADCs. In recent years, a variety of ADCs are being investigated in phases I and II trials, emerging data of which shows promising effects. At present, Creative Biolabs possesses new linker technology as well as novel highly potent cytotoxic payloads, and we are confident in developing more effective and safe ADCs for the kidney cancer. Our ADC development service against renal cancer including but not limited to:

RCC

Creative Biolabs offers a top-ranking ADC design and development services targeting renal cancer. Our team of experts together with our broad services portfolio make us confident in offering high-quality services in a time-saving and cost-effective manner. We are happy to help you speed your project progress and achieving ideal research goals. If you are interested in our service, please do not hesitate to contact us for more details.

ADC Development for Renal Cancer


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top